Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 1

1(33.3%)

3Total

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01519908Completed

Markers and Response to Cardiac Resynchronization Therapy

Role: collaborator

NCT01709045Completed

ParisK: Correlation of Imaging Techniques With Histology

Role: collaborator

NCT03749850Phase 1Unknown

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

Role: collaborator

NCT02954588Not ApplicableCompleted

Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity

Role: collaborator

NCT01905033Unknown

Molecular Diagnosis and Risk Stratification of Sepsis

Role: collaborator

NCT01450891Completed

Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease

Role: collaborator

NCT00943059Not ApplicableCompleted

Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function

Role: collaborator

All 7 trials loaded